AR
Design armored CAR-T cells with cytokine payloads and resistance mechanisms.
FreedomIntelligence/OpenClaw-Medical-Skills查看
数据与复现
MP
mpn-progression-monitor-agent
维护者 FreedomIntelligence · 最近更新 2026年4月1日
Myeloproliferative neoplasm progression monitoring from serial molecular data.
原始来源
FreedomIntelligence/OpenClaw-Medical-Skills
https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/mpn-progression-monitor-agent
- 维护者
- FreedomIntelligence
- 许可
- MIT
- 最近更新
- 2026年4月1日
技能摘要
来自 SKILL.md 的关键信息
核心说明
- MPN Progression Monitor Agent provides comprehensive monitoring of myeloproliferative neoplasms (PV，ET，MF) ，用于 disease progression，treatment response，、 transformation risk. It integrates molecular profiling，clinical parameters，、 AI-based risk models to guide management of chronic phase disease 、 predict blast transformation。
- When monitoring JAK2/CALR/MPL mutation burden over time。
- 用于 predicting fibrosis progression in PV/ET。
- To assess risk of blast transformation。
- When tracking treatment response to JAK inhibitors。
原始文档
SKILL.md 摘录
Core Capabilities
-
Mutation Monitoring: Track driver and high-risk mutation VAF.
-
Progression Prediction: Model fibrosis and transformation risk.
-
Risk Scoring: Calculate DIPSS, MIPSS70+, MTSS dynamically.
-
Treatment Response: Assess molecular and clinical response.
-
Clone Evolution: Track clonal dynamics and new mutations.
-
Transplant Timing: Optimize allo-HSCT timing decisions.
MPN Classification
| MPN Type | Driver Mutations | Progression Risk |
|---|---|---|
| PV | JAK2 V617F (95%), JAK2 exon 12 | Fibrosis 10-15%, AML 2-5% |
| ET | JAK2 (55%), CALR (25%), MPL (5%) | Fibrosis 5-10%, AML 1-2% |
| Pre-PMF | Same as PMF | Variable |
| PMF | JAK2 (60%), CALR (25%), MPL (5%) | AML 10-20% |
High-Risk Mutations
| Mutation | Impact | MF Association |
|---|---|---|
| ASXL1 | Adverse | Strong |
| SRSF2 | Adverse | Strong (PMF) |
| EZH2 | Adverse | Moderate |
| IDH1/2 | Adverse | Transformation |
| RUNX1 | Very Adverse | Transformation |
| TP53 | Very Adverse | Transformation |
| U2AF1 | Adverse | Moderate |
适用场景
- When monitoring JAK2/CALR/MPL mutation burden over time。
- 用于 predicting fibrosis progression in PV/ET。
- To assess risk of blast transformation。
- When tracking treatment response to JAK inhibitors。
不适用场景
- Do not rely on this catalog entry alone ，用于 installation 或 maintenance details。
上游相关技能
- CHIP_Clonal_Hematopoiesis_Agent - Pre-MPN states
- MDS_Classification_Agent - Overlap syndromes
- Bone_Marrow_AI_Agent - Morphology analysis
- Coagulation_Thrombosis_Agent - Thrombosis risk
相关技能
相关技能
AR
数据与复现
arxiv-search
Search arXiv physics, math, and computer science preprints using natural language queries. Powered by Valyu semantic sea…
FreedomIntelligence/OpenClaw-Medical-Skills查看
AU
Autonomous oncology research agent: literature mining, trial matching, biomarker analysis, and treatment hypothesis gene…
FreedomIntelligence/OpenClaw-Medical-Skills查看
BI
Preprocesses cell-free DNA sequencing data including adapter trimming, alignment optimized for short fragments, and UMI-…
FreedomIntelligence/OpenClaw-Medical-Skills查看